Glucagon-like peptide 1-based drugs and pancreatic safety--reply

Affiliations

¹ Department of Medicine and the Center for Public Health and Human Rights, Johns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland.

Comment

Sonal Singh. JAMA Intern Med. 2013.

. 2013 Oct 28;173(19):1843-4.

doi: 10.1001/jamainternmed.2013.8128.

¹ Department of Medicine and the Center for Public Health and Human Rights, Johns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland.

No abstract available

Comment on

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Singh S, et al. JAMA Intern Med. 2013 Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720. JAMA Intern Med. 2013. PMID: 23440284
Glucagon-like peptide 1-based drugs and pancreatic safety.
Brodovicz KG, Engel SS, Thornberry NA. Brodovicz KG, et al. JAMA Intern Med. 2013 Oct 28;173(19):1842-3. doi: 10.1001/jamainternmed.2013.8138. JAMA Intern Med. 2013. PMID: 24165844 No abstract available.
Glucagon-like peptide 1-based drugs and pancreatic safety.
Raschi E, Piccinni C, Marchesini G. Raschi E, et al. JAMA Intern Med. 2013 Oct 28;173(19):1843. doi: 10.1001/jamainternmed.2013.8150. JAMA Intern Med. 2013. PMID: 24165845 No abstract available.